 Pamela Zeitlin
Concepts (482)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis Transmembrane Conductance Regulator | 45 | 2022 | 312 | 7.120 |
Why?
| | Cystic Fibrosis | 68 | 2022 | 1049 | 6.260 |
Why?
| | Chlorides | 11 | 2020 | 137 | 1.550 |
Why?
| | Chloride Channels | 12 | 2013 | 38 | 1.540 |
Why?
| | Benzodioxoles | 6 | 2022 | 105 | 1.200 |
Why?
| | Bronchi | 9 | 2012 | 241 | 1.090 |
Why?
| | Epithelial Cells | 13 | 2024 | 1043 | 1.070 |
Why?
| | Mutation | 18 | 2022 | 3696 | 1.030 |
Why?
| | Nasal Mucosa | 11 | 2024 | 107 | 0.960 |
Why?
| | Interleukin-8 | 8 | 2017 | 262 | 0.850 |
Why?
| | Phenylbutyrates | 5 | 2006 | 22 | 0.790 |
Why?
| | Indoles | 3 | 2022 | 372 | 0.760 |
Why?
| | Alprostadil | 2 | 2013 | 32 | 0.720 |
Why?
| | Respiratory Mucosa | 8 | 2024 | 304 | 0.670 |
Why?
| | Aminophenols | 6 | 2022 | 144 | 0.670 |
Why?
| | Endoplasmic Reticulum | 9 | 2014 | 260 | 0.590 |
Why?
| | Dependovirus | 5 | 2007 | 62 | 0.580 |
Why?
| | Genetic Therapy | 8 | 2011 | 292 | 0.570 |
Why?
| | Digitoxin | 1 | 2017 | 3 | 0.550 |
Why?
| | Pseudomonas Infections | 5 | 2020 | 218 | 0.550 |
Why?
| | Epithelium | 5 | 2021 | 306 | 0.540 |
Why?
| | Ubiquitin | 2 | 2014 | 62 | 0.530 |
Why?
| | Lung | 11 | 2022 | 3748 | 0.520 |
Why?
| | Protein Processing, Post-Translational | 3 | 2014 | 453 | 0.520 |
Why?
| | Mucociliary Clearance | 3 | 2021 | 42 | 0.500 |
Why?
| | Proteomics | 3 | 2012 | 1018 | 0.500 |
Why?
| | Proteasome Endopeptidase Complex | 3 | 2014 | 145 | 0.480 |
Why?
| | Sputum | 10 | 2020 | 301 | 0.480 |
Why?
| | Sp1 Transcription Factor | 2 | 2006 | 24 | 0.470 |
Why?
| | Anti-Inflammatory Agents | 2 | 2017 | 470 | 0.460 |
Why?
| | Ion Transport | 5 | 2020 | 57 | 0.420 |
Why?
| | Scorpion Venoms | 1 | 2013 | 3 | 0.420 |
Why?
| | Gene Expression Regulation | 7 | 2009 | 2516 | 0.400 |
Why?
| | Cell Line | 11 | 2014 | 2741 | 0.390 |
Why?
| | Protein Array Analysis | 2 | 2012 | 56 | 0.390 |
Why?
| | Pseudomonas aeruginosa | 4 | 2016 | 344 | 0.390 |
Why?
| | Humans | 80 | 2024 | 128499 | 0.380 |
Why?
| | Lysine | 1 | 2014 | 285 | 0.380 |
Why?
| | Lubiprostone | 3 | 2022 | 9 | 0.380 |
Why?
| | Inflammation | 3 | 2017 | 2666 | 0.350 |
Why?
| | NF-kappa B | 4 | 2009 | 650 | 0.350 |
Why?
| | Respiratory System | 3 | 2022 | 152 | 0.340 |
Why?
| | Quinolones | 4 | 2022 | 126 | 0.340 |
Why?
| | Trachea | 3 | 2008 | 221 | 0.340 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2010 | 42 | 0.330 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2006 | 819 | 0.330 |
Why?
| | Caveolin 1 | 1 | 2009 | 18 | 0.320 |
Why?
| | Aspergillus fumigatus | 1 | 2008 | 23 | 0.310 |
Why?
| | Estrogen Antagonists | 1 | 2008 | 45 | 0.310 |
Why?
| | Endocytosis | 1 | 2009 | 161 | 0.300 |
Why?
| | Dinoprostone | 3 | 2022 | 187 | 0.300 |
Why?
| | Proteome | 4 | 2009 | 432 | 0.290 |
Why?
| | Protein Folding | 4 | 2004 | 266 | 0.290 |
Why?
| | Tamoxifen | 1 | 2008 | 200 | 0.290 |
Why?
| | Calcium | 3 | 2008 | 1183 | 0.280 |
Why?
| | Transcription Factor CHOP | 1 | 2007 | 30 | 0.280 |
Why?
| | Ofloxacin | 1 | 2007 | 24 | 0.270 |
Why?
| | Levofloxacin | 1 | 2007 | 25 | 0.270 |
Why?
| | Drugs, Investigational | 1 | 2007 | 32 | 0.270 |
Why?
| | Adolescent | 31 | 2020 | 20304 | 0.270 |
Why?
| | S-Nitrosoglutathione | 1 | 2006 | 7 | 0.270 |
Why?
| | Mutant Proteins | 1 | 2007 | 99 | 0.260 |
Why?
| | Adult | 34 | 2022 | 35302 | 0.260 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2006 | 21 | 0.260 |
Why?
| | Nebulizers and Vaporizers | 2 | 2005 | 81 | 0.260 |
Why?
| | Interleukin-13 | 2 | 2024 | 144 | 0.250 |
Why?
| | Membrane Potentials | 5 | 2013 | 264 | 0.250 |
Why?
| | Pneumonia, Bacterial | 1 | 2007 | 112 | 0.250 |
Why?
| | Genetic Testing | 1 | 2008 | 428 | 0.250 |
Why?
| | Chloride Channel Agonists | 2 | 2021 | 77 | 0.250 |
Why?
| | Sinusitis | 3 | 2020 | 203 | 0.240 |
Why?
| | Aerosols | 2 | 2005 | 168 | 0.240 |
Why?
| | Estradiol | 1 | 2008 | 489 | 0.240 |
Why?
| | Water | 1 | 2008 | 442 | 0.240 |
Why?
| | Positive-Pressure Respiration | 1 | 2005 | 75 | 0.240 |
Why?
| | Anti-Bacterial Agents | 6 | 2014 | 1705 | 0.240 |
Why?
| | Proteins | 3 | 2012 | 936 | 0.240 |
Why?
| | Respiratory Function Tests | 6 | 2021 | 580 | 0.240 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1357 | 0.240 |
Why?
| | Homeostasis | 1 | 2008 | 606 | 0.230 |
Why?
| | Pyrrolidines | 2 | 2022 | 67 | 0.230 |
Why?
| | Curcumin | 1 | 2004 | 28 | 0.220 |
Why?
| | Lectins | 1 | 2024 | 46 | 0.220 |
Why?
| | Flavonoids | 1 | 2004 | 78 | 0.220 |
Why?
| | GPI-Linked Proteins | 1 | 2024 | 67 | 0.220 |
Why?
| | Mucin 5AC | 1 | 2024 | 69 | 0.220 |
Why?
| | Mucus | 1 | 2024 | 75 | 0.210 |
Why?
| | Plicamycin | 1 | 2003 | 3 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2017 | 1951 | 0.210 |
Why?
| | Genetic Vectors | 5 | 2005 | 311 | 0.210 |
Why?
| | Female | 39 | 2020 | 68268 | 0.210 |
Why?
| | Membrane Proteins | 2 | 2006 | 1109 | 0.210 |
Why?
| | Immunity, Innate | 1 | 2009 | 803 | 0.200 |
Why?
| | Male | 37 | 2020 | 63045 | 0.200 |
Why?
| | Forced Expiratory Volume | 6 | 2018 | 511 | 0.200 |
Why?
| | Amniotic Fluid | 1 | 2003 | 86 | 0.200 |
Why?
| | Signal Transduction | 4 | 2022 | 4825 | 0.200 |
Why?
| | Cell Cycle Proteins | 1 | 2006 | 581 | 0.200 |
Why?
| | Receptors, Prostaglandin E, EP2 Subtype | 1 | 2022 | 6 | 0.190 |
Why?
| | Peptides, Cyclic | 1 | 2004 | 255 | 0.190 |
Why?
| | Heterozygote | 2 | 2021 | 269 | 0.190 |
Why?
| | Prostaglandins | 1 | 2022 | 85 | 0.190 |
Why?
| | Animals | 19 | 2022 | 34647 | 0.190 |
Why?
| | Nanoparticles | 3 | 2011 | 369 | 0.190 |
Why?
| | Biological Transport | 3 | 2008 | 396 | 0.190 |
Why?
| | Child | 26 | 2024 | 20805 | 0.190 |
Why?
| | Pyrazoles | 2 | 2022 | 404 | 0.180 |
Why?
| | Pyridines | 2 | 2022 | 474 | 0.180 |
Why?
| | Oxadiazoles | 2 | 2014 | 33 | 0.180 |
Why?
| | Epithelial Sodium Channels | 1 | 2021 | 18 | 0.180 |
Why?
| | Aminopyridines | 2 | 2021 | 95 | 0.170 |
Why?
| | Quinolines | 1 | 2021 | 155 | 0.170 |
Why?
| | Tobramycin | 4 | 2014 | 51 | 0.160 |
Why?
| | Protein Structure, Tertiary | 2 | 2014 | 837 | 0.160 |
Why?
| | Antibodies, Viral | 2 | 2003 | 601 | 0.160 |
Why?
| | Protein Transport | 3 | 2014 | 421 | 0.160 |
Why?
| | Mice | 10 | 2022 | 16620 | 0.160 |
Why?
| | Paranasal Sinuses | 1 | 2020 | 74 | 0.160 |
Why?
| | Molecular Chaperones | 3 | 2008 | 182 | 0.160 |
Why?
| | Ergocalciferols | 2 | 2010 | 11 | 0.160 |
Why?
| | Ataxia Telangiectasia | 2 | 2010 | 17 | 0.160 |
Why?
| | Double-Blind Method | 6 | 2017 | 1856 | 0.160 |
Why?
| | Pulmonary Medicine | 2 | 2010 | 78 | 0.160 |
Why?
| | Genotype | 6 | 2021 | 1830 | 0.150 |
Why?
| | Cyclic AMP | 3 | 2008 | 231 | 0.150 |
Why?
| | Immunoglobulin G | 1 | 2003 | 844 | 0.150 |
Why?
| | Asthma | 2 | 2024 | 2213 | 0.150 |
Why?
| | Administration, Intranasal | 4 | 2007 | 83 | 0.150 |
Why?
| | Subcellular Fractions | 2 | 2008 | 80 | 0.150 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2020 | 205 | 0.150 |
Why?
| | Sweat | 4 | 2016 | 46 | 0.150 |
Why?
| | Administration, Inhalation | 8 | 2007 | 661 | 0.150 |
Why?
| | Vitamins | 2 | 2010 | 174 | 0.140 |
Why?
| | Cell Membrane | 2 | 2014 | 725 | 0.140 |
Why?
| | Biomarkers | 4 | 2017 | 3893 | 0.140 |
Why?
| | Respiratory Tract Infections | 3 | 2008 | 372 | 0.140 |
Why?
| | Membrane Transport Modulators | 1 | 2017 | 7 | 0.140 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2017 | 27 | 0.140 |
Why?
| | Maryland | 1 | 2017 | 45 | 0.140 |
Why?
| | Vitamin D Deficiency | 2 | 2010 | 176 | 0.140 |
Why?
| | Lung Diseases | 1 | 2003 | 715 | 0.140 |
Why?
| | Mice, Knockout | 3 | 2009 | 2765 | 0.130 |
Why?
| | Rifampin | 1 | 2017 | 85 | 0.130 |
Why?
| | Adenosine Triphosphate | 2 | 2008 | 469 | 0.130 |
Why?
| | Leukocyte Count | 1 | 2017 | 326 | 0.130 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1423 | 0.120 |
Why?
| | Computational Biology | 2 | 2012 | 597 | 0.120 |
Why?
| | Drug Combinations | 3 | 2022 | 324 | 0.120 |
Why?
| | Transcription Factors | 1 | 2003 | 1635 | 0.120 |
Why?
| | Young Adult | 9 | 2020 | 12349 | 0.120 |
Why?
| | Gene Transfer Techniques | 3 | 2005 | 162 | 0.120 |
Why?
| | Child, Preschool | 11 | 2021 | 10487 | 0.120 |
Why?
| | Drug Design | 2 | 2007 | 155 | 0.110 |
Why?
| | Cell Line, Transformed | 2 | 2006 | 141 | 0.110 |
Why?
| | Sodium Chloride | 2 | 2005 | 138 | 0.110 |
Why?
| | Ubiquitination | 1 | 2014 | 98 | 0.110 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 2 | 2016 | 11 | 0.110 |
Why?
| | Exocrine Pancreatic Insufficiency | 2 | 2016 | 20 | 0.110 |
Why?
| | Amiloride | 2 | 2004 | 23 | 0.110 |
Why?
| | Cells, Cultured | 4 | 2021 | 4017 | 0.110 |
Why?
| | Protein Stability | 1 | 2014 | 160 | 0.110 |
Why?
| | Proteolysis | 1 | 2014 | 162 | 0.110 |
Why?
| | Sleep | 1 | 2019 | 682 | 0.110 |
Why?
| | Isoproterenol | 2 | 2004 | 112 | 0.110 |
Why?
| | Mass Spectrometry | 2 | 2014 | 663 | 0.110 |
Why?
| | Pediatrics | 3 | 2010 | 1050 | 0.100 |
Why?
| | Promoter Regions, Genetic | 3 | 2009 | 1199 | 0.100 |
Why?
| | Neutrophils | 2 | 2017 | 1192 | 0.100 |
Why?
| | Phenotype | 6 | 2016 | 3051 | 0.100 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 3 | 2009 | 98 | 0.100 |
Why?
| | RNA, Messenger | 4 | 2008 | 2679 | 0.100 |
Why?
| | Colforsin | 2 | 2021 | 49 | 0.100 |
Why?
| | Enzyme Inhibitors | 2 | 2006 | 813 | 0.090 |
Why?
| | HEK293 Cells | 1 | 2014 | 683 | 0.090 |
Why?
| | Down-Regulation | 3 | 2021 | 632 | 0.090 |
Why?
| | Expectorants | 1 | 2011 | 24 | 0.090 |
Why?
| | Staining and Labeling | 1 | 2012 | 137 | 0.090 |
Why?
| | Age Factors | 2 | 2017 | 3122 | 0.090 |
Why?
| | Protein Conformation | 1 | 2014 | 854 | 0.090 |
Why?
| | Mice, Inbred C57BL | 3 | 2013 | 5281 | 0.090 |
Why?
| | Research Personnel | 2 | 2010 | 156 | 0.090 |
Why?
| | Transduction, Genetic | 1 | 2011 | 128 | 0.090 |
Why?
| | Acetylcysteine | 1 | 2011 | 142 | 0.090 |
Why?
| | Vital Capacity | 1 | 2011 | 291 | 0.090 |
Why?
| | Endopeptidases | 1 | 2010 | 85 | 0.080 |
Why?
| | Cervix Mucus | 1 | 2009 | 1 | 0.080 |
Why?
| | Anhydrides | 1 | 2009 | 18 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 724 | 0.080 |
Why?
| | Rats | 4 | 2009 | 5246 | 0.080 |
Why?
| | Homozygote | 1 | 2010 | 193 | 0.080 |
Why?
| | Membrane Microdomains | 1 | 2009 | 31 | 0.080 |
Why?
| | Posterior Horn Cells | 1 | 2009 | 5 | 0.080 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2009 | 102 | 0.080 |
Why?
| | Models, Biological | 2 | 2007 | 1698 | 0.080 |
Why?
| | Synaptosomes | 1 | 2009 | 30 | 0.080 |
Why?
| | Models, Molecular | 1 | 2014 | 1484 | 0.080 |
Why?
| | Spiperone | 1 | 2008 | 1 | 0.080 |
Why?
| | Endoscopy | 1 | 2011 | 271 | 0.080 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 310 | 0.080 |
Why?
| | Drug Carriers | 1 | 2009 | 116 | 0.080 |
Why?
| | Nutrition Assessment | 1 | 2009 | 85 | 0.080 |
Why?
| | Ribosomes | 1 | 2010 | 164 | 0.080 |
Why?
| | Electric Conductivity | 1 | 2008 | 94 | 0.080 |
Why?
| | Respiratory System Agents | 1 | 2008 | 22 | 0.080 |
Why?
| | Administration, Topical | 1 | 2008 | 144 | 0.070 |
Why?
| | Polyethylene Glycols | 2 | 2011 | 600 | 0.070 |
Why?
| | Biopsy | 1 | 2012 | 1079 | 0.070 |
Why?
| | Malnutrition | 1 | 2009 | 79 | 0.070 |
Why?
| | Codon, Terminator | 2 | 2007 | 21 | 0.070 |
Why?
| | Fibrous Dysplasia, Polyostotic | 1 | 2007 | 7 | 0.070 |
Why?
| | Tissue Distribution | 2 | 2005 | 296 | 0.070 |
Why?
| | Blotting, Western | 2 | 2007 | 1170 | 0.070 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 1 | 2007 | 9 | 0.070 |
Why?
| | Statistics, Nonparametric | 2 | 2005 | 419 | 0.070 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2069 | 0.070 |
Why?
| | Adenoviridae | 2 | 2005 | 189 | 0.070 |
Why?
| | Treatment Outcome | 9 | 2018 | 10162 | 0.070 |
Why?
| | Cytosol | 1 | 2008 | 215 | 0.070 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2007 | 131 | 0.070 |
Why?
| | Aminoglycosides | 1 | 2007 | 23 | 0.070 |
Why?
| | Airway Obstruction | 1 | 2008 | 149 | 0.070 |
Why?
| | Technology, Pharmaceutical | 1 | 2007 | 18 | 0.070 |
Why?
| | Ibuprofen | 1 | 2007 | 81 | 0.070 |
Why?
| | Metabolic Clearance Rate | 1 | 2007 | 108 | 0.070 |
Why?
| | Mannose-Binding Lectin | 1 | 2006 | 22 | 0.070 |
Why?
| | Socioeconomic Factors | 1 | 2011 | 1212 | 0.070 |
Why?
| | Cyclooxygenase 2 | 1 | 2007 | 178 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2007 | 145 | 0.070 |
Why?
| | Nutritional Status | 1 | 2009 | 326 | 0.070 |
Why?
| | HSP40 Heat-Shock Proteins | 1 | 2006 | 24 | 0.070 |
Why?
| | Valosin Containing Protein | 1 | 2006 | 4 | 0.070 |
Why?
| | Polysaccharide-Lyases | 1 | 2006 | 11 | 0.070 |
Why?
| | DNA Primers | 1 | 2007 | 510 | 0.060 |
Why?
| | Tunicamycin | 1 | 2006 | 11 | 0.060 |
Why?
| | Proteasome Inhibitors | 1 | 2006 | 42 | 0.060 |
Why?
| | DNA, Viral | 2 | 2005 | 348 | 0.060 |
Why?
| | Chondroitin Sulfates | 1 | 2006 | 34 | 0.060 |
Why?
| | CHO Cells | 1 | 2006 | 151 | 0.060 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2005 | 7 | 0.060 |
Why?
| | Gamma Cameras | 1 | 2005 | 7 | 0.060 |
Why?
| | Luciferases | 2 | 2003 | 147 | 0.060 |
Why?
| | Cricetinae | 1 | 2006 | 276 | 0.060 |
Why?
| | Spinal Cord Injuries | 1 | 2009 | 192 | 0.060 |
Why?
| | Radionuclide Imaging | 1 | 2005 | 122 | 0.060 |
Why?
| | Nitric Oxide Synthase | 1 | 2006 | 230 | 0.060 |
Why?
| | Glycosylation | 1 | 2006 | 149 | 0.060 |
Why?
| | Glutamine | 1 | 2006 | 94 | 0.060 |
Why?
| | Purinergic P2 Receptor Agonists | 1 | 2005 | 4 | 0.060 |
Why?
| | Precision Medicine | 1 | 2009 | 386 | 0.060 |
Why?
| | Adenosine Triphosphatases | 1 | 2006 | 161 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 941 | 0.060 |
Why?
| | Deoxycytosine Nucleotides | 1 | 2005 | 11 | 0.060 |
Why?
| | Uridine | 1 | 2005 | 29 | 0.060 |
Why?
| | Chronic Disease | 2 | 2008 | 1692 | 0.060 |
Why?
| | Nerve Tissue Proteins | 1 | 2009 | 570 | 0.060 |
Why?
| | Radiopharmaceuticals | 1 | 2005 | 166 | 0.060 |
Why?
| | Acidosis | 1 | 2006 | 88 | 0.060 |
Why?
| | Polymers | 1 | 2009 | 475 | 0.060 |
Why?
| | DNA | 1 | 2011 | 1394 | 0.060 |
Why?
| | Gene Expression Profiling | 3 | 2006 | 1689 | 0.060 |
Why?
| | Particle Size | 1 | 2005 | 352 | 0.060 |
Why?
| | Nasal Polyps | 1 | 2004 | 57 | 0.060 |
Why?
| | Inhalation Exposure | 1 | 2004 | 89 | 0.050 |
Why?
| | Dietary Supplements | 1 | 2008 | 531 | 0.050 |
Why?
| | Base Sequence | 1 | 2007 | 2137 | 0.050 |
Why?
| | Biomedical Research | 1 | 2010 | 633 | 0.050 |
Why?
| | Bronchial Provocation Tests | 1 | 2003 | 50 | 0.050 |
Why?
| | Transfection | 1 | 2006 | 896 | 0.050 |
Why?
| | Drug Administration Schedule | 4 | 2010 | 764 | 0.050 |
Why?
| | Sp3 Transcription Factor | 1 | 2003 | 5 | 0.050 |
Why?
| | Recombinant Fusion Proteins | 2 | 2003 | 636 | 0.050 |
Why?
| | Diuretics | 1 | 2003 | 75 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2004 | 268 | 0.050 |
Why?
| | Heat-Shock Proteins | 1 | 2004 | 134 | 0.050 |
Why?
| | RNA Interference | 1 | 2005 | 441 | 0.050 |
Why?
| | Protein Denaturation | 1 | 2003 | 75 | 0.050 |
Why?
| | Xanthines | 1 | 2002 | 18 | 0.050 |
Why?
| | Isoflavones | 1 | 2002 | 25 | 0.050 |
Why?
| | Clinical Protocols | 1 | 2004 | 254 | 0.050 |
Why?
| | Sex Factors | 1 | 2008 | 1951 | 0.050 |
Why?
| | 5' Flanking Region | 1 | 2002 | 8 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 2 | 2008 | 2269 | 0.050 |
Why?
| | Biological Transport, Active | 1 | 2002 | 72 | 0.050 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2002 | 85 | 0.050 |
Why?
| | Disease Progression | 3 | 2017 | 2604 | 0.050 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2002 | 149 | 0.050 |
Why?
| | Aging | 2 | 2003 | 1755 | 0.050 |
Why?
| | Carrier State | 1 | 2002 | 60 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2004 | 1003 | 0.050 |
Why?
| | Dimethyl Sulfoxide | 1 | 2022 | 41 | 0.050 |
Why?
| | 1-Methyl-3-isobutylxanthine | 1 | 2021 | 22 | 0.050 |
Why?
| | Anesthesiologists | 1 | 2022 | 11 | 0.050 |
Why?
| | Forecasting | 1 | 2003 | 356 | 0.050 |
Why?
| | Bronchodilator Agents | 1 | 2003 | 243 | 0.050 |
Why?
| | Patient Acceptance of Health Care | 1 | 2008 | 757 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1187 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2005 | 761 | 0.050 |
Why?
| | NIH 3T3 Cells | 1 | 2021 | 141 | 0.050 |
Why?
| | Point Mutation | 1 | 2002 | 225 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2003 | 378 | 0.050 |
Why?
| | Electrophysiology | 1 | 2021 | 205 | 0.050 |
Why?
| | Infant | 4 | 2020 | 9001 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2004 | 1016 | 0.050 |
Why?
| | Genetic Variation | 1 | 2006 | 935 | 0.050 |
Why?
| | Up-Regulation | 1 | 2004 | 823 | 0.050 |
Why?
| | Occupational Exposure | 1 | 2004 | 299 | 0.040 |
Why?
| | Nitric Oxide | 1 | 2006 | 881 | 0.040 |
Why?
| | Codon, Nonsense | 2 | 2014 | 39 | 0.040 |
Why?
| | Polymorphism, Genetic | 1 | 2024 | 639 | 0.040 |
Why?
| | Anti-Infective Agents | 1 | 2003 | 245 | 0.040 |
Why?
| | Middle Aged | 8 | 2020 | 30923 | 0.040 |
Why?
| | Respiration | 1 | 2021 | 190 | 0.040 |
Why?
| | Drug Monitoring | 2 | 2017 | 190 | 0.040 |
Why?
| | Nasal Surgical Procedures | 1 | 2020 | 6 | 0.040 |
Why?
| | Viscosity | 2 | 2011 | 89 | 0.040 |
Why?
| | Cell Survival | 1 | 2003 | 1076 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2002 | 808 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1404 | 0.040 |
Why?
| | Patient Care Team | 1 | 2004 | 598 | 0.040 |
Why?
| | Cytokines | 2 | 2024 | 1994 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2017 | 624 | 0.040 |
Why?
| | Albuterol | 1 | 2019 | 103 | 0.040 |
Why?
| | Spirometry | 1 | 2019 | 254 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1668 | 0.040 |
Why?
| | Biological Products | 1 | 2021 | 199 | 0.040 |
Why?
| | Haplotypes | 1 | 2020 | 471 | 0.040 |
Why?
| | Retrospective Studies | 5 | 2020 | 14472 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2710 | 0.040 |
Why?
| | Temperature | 1 | 2021 | 632 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 5 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2019 | 509 | 0.030 |
Why?
| | Bacteria | 1 | 2003 | 817 | 0.030 |
Why?
| | Biological Availability | 1 | 2017 | 131 | 0.030 |
Why?
| | Biphenyl Compounds | 1 | 2017 | 60 | 0.030 |
Why?
| | Seasons | 2 | 2010 | 498 | 0.030 |
Why?
| | Fellowships and Scholarships | 2 | 2010 | 272 | 0.030 |
Why?
| | DNA, Bacterial | 1 | 2017 | 324 | 0.030 |
Why?
| | Drug Interactions | 1 | 2017 | 361 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2017 | 172 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2003 | 1900 | 0.030 |
Why?
| | China | 1 | 2016 | 190 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2016 | 139 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 982 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2017 | 3339 | 0.030 |
Why?
| | Exons | 1 | 2016 | 339 | 0.030 |
Why?
| | Bronchiectasis | 1 | 2016 | 108 | 0.030 |
Why?
| | Colony Count, Microbial | 2 | 2005 | 116 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1499 | 0.030 |
Why?
| | Time Factors | 3 | 2010 | 6506 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2005 | 2042 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2007 | 1027 | 0.030 |
Why?
| | Genes, Reporter | 2 | 2005 | 266 | 0.030 |
Why?
| | Prevalence | 2 | 2010 | 2553 | 0.020 |
Why?
| | Polylysine | 1 | 2011 | 17 | 0.020 |
Why?
| | Biopolymers | 1 | 2011 | 33 | 0.020 |
Why?
| | Diffusion | 1 | 2011 | 118 | 0.020 |
Why?
| | Mucins | 1 | 2011 | 70 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2010 | 4874 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2009 | 2272 | 0.020 |
Why?
| | Plasmids | 1 | 2011 | 355 | 0.020 |
Why?
| | Pregnancy | 1 | 2003 | 6373 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2517 | 0.020 |
Why?
| | CD4-CD8 Ratio | 1 | 2010 | 22 | 0.020 |
Why?
| | 25-Hydroxyvitamin D 2 | 1 | 2010 | 5 | 0.020 |
Why?
| | alpha-Fetoproteins | 1 | 2010 | 40 | 0.020 |
Why?
| | Calcifediol | 1 | 2010 | 31 | 0.020 |
Why?
| | Accreditation | 1 | 2010 | 80 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2011 | 5045 | 0.020 |
Why?
| | Societies, Scientific | 1 | 2009 | 45 | 0.020 |
Why?
| | Immunoassay | 1 | 2010 | 104 | 0.020 |
Why?
| | Indicator Dilution Techniques | 1 | 2009 | 11 | 0.020 |
Why?
| | Adhesiveness | 1 | 2009 | 19 | 0.020 |
Why?
| | Mice, Inbred CFTR | 1 | 2008 | 5 | 0.020 |
Why?
| | Cohort Studies | 2 | 2011 | 5402 | 0.020 |
Why?
| | Type C Phospholipases | 1 | 2008 | 72 | 0.020 |
Why?
| | Baltimore | 1 | 2008 | 44 | 0.020 |
Why?
| | Biological Assay | 1 | 2008 | 118 | 0.020 |
Why?
| | Small Molecule Libraries | 1 | 2008 | 86 | 0.020 |
Why?
| | Drug Discovery | 1 | 2008 | 130 | 0.020 |
Why?
| | Cell Polarity | 1 | 2008 | 140 | 0.020 |
Why?
| | Hospitals, University | 1 | 2008 | 176 | 0.020 |
Why?
| | Quality of Life | 1 | 2019 | 2688 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2010 | 398 | 0.020 |
Why?
| | Career Choice | 1 | 2009 | 207 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 367 | 0.020 |
Why?
| | Placebos | 1 | 2007 | 201 | 0.020 |
Why?
| | Solutions | 1 | 2007 | 148 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2009 | 375 | 0.020 |
Why?
| | Gentamicins | 1 | 2007 | 52 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 7069 | 0.020 |
Why?
| | Sulfur Radioisotopes | 1 | 2006 | 16 | 0.020 |
Why?
| | Silver Staining | 1 | 2006 | 17 | 0.020 |
Why?
| | Dual Oxidases | 1 | 2006 | 2 | 0.020 |
Why?
| | Flavoproteins | 1 | 2006 | 8 | 0.020 |
Why?
| | Salivary Proteins and Peptides | 1 | 2006 | 13 | 0.020 |
Why?
| | Comorbidity | 1 | 2011 | 1541 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 779 | 0.020 |
Why?
| | Peptide Mapping | 1 | 2006 | 61 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2008 | 261 | 0.020 |
Why?
| | Energy Intake | 1 | 2009 | 454 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2006 | 137 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2008 | 558 | 0.020 |
Why?
| | NADPH Oxidases | 1 | 2006 | 107 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 2006 | 80 | 0.020 |
Why?
| | Blotting, Southern | 1 | 2005 | 68 | 0.020 |
Why?
| | Methionine | 1 | 2006 | 157 | 0.020 |
Why?
| | Serum | 1 | 2006 | 57 | 0.020 |
Why?
| | Education, Medical, Graduate | 1 | 2010 | 435 | 0.020 |
Why?
| | Societies, Medical | 1 | 2009 | 744 | 0.020 |
Why?
| | Receptors, Purinergic P2Y2 | 1 | 2005 | 6 | 0.020 |
Why?
| | Helper Viruses | 1 | 2005 | 2 | 0.020 |
Why?
| | Severity of Illness Index | 2 | 2004 | 2719 | 0.010 |
Why?
| | Burkholderia | 1 | 2005 | 13 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2008 | 431 | 0.010 |
Why?
| | Nasal Cavity | 1 | 2005 | 50 | 0.010 |
Why?
| | Pancreatic Elastase | 1 | 2005 | 59 | 0.010 |
Why?
| | Hemoptysis | 1 | 2005 | 33 | 0.010 |
Why?
| | Peroxidase | 1 | 2005 | 169 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 541 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2006 | 856 | 0.010 |
Why?
| | Quality of Health Care | 1 | 2009 | 606 | 0.010 |
Why?
| | Reference Values | 1 | 2006 | 780 | 0.010 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2004 | 43 | 0.010 |
Why?
| | Syndrome | 1 | 2004 | 336 | 0.010 |
Why?
| | Siblings | 1 | 2004 | 215 | 0.010 |
Why?
| | Antibodies | 1 | 2006 | 394 | 0.010 |
Why?
| | DNA, Recombinant | 1 | 2003 | 46 | 0.010 |
Why?
| | Treatment Failure | 1 | 2004 | 338 | 0.010 |
Why?
| | Saline Solution, Hypertonic | 1 | 2003 | 38 | 0.010 |
Why?
| | Heating | 1 | 2003 | 20 | 0.010 |
Why?
| | Survival Analysis | 1 | 2006 | 1265 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 1200 | 0.010 |
Why?
| | Virus Shedding | 1 | 2003 | 47 | 0.010 |
Why?
| | Survivors | 1 | 2006 | 462 | 0.010 |
Why?
| | Dyspnea | 1 | 2005 | 239 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 1980 | 0.010 |
Why?
| | Hearing Disorders | 1 | 2002 | 9 | 0.010 |
Why?
| | Probability | 1 | 2004 | 306 | 0.010 |
Why?
| | Audiometry | 1 | 2002 | 27 | 0.010 |
Why?
| | Bronchoscopy | 1 | 2004 | 208 | 0.010 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2002 | 21 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2003 | 316 | 0.010 |
Why?
| | Oropharynx | 1 | 2002 | 43 | 0.010 |
Why?
| | United States | 2 | 2010 | 13840 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2009 | 1191 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2003 | 394 | 0.010 |
Why?
| | Viremia | 1 | 2003 | 131 | 0.010 |
Why?
| | Embryonic and Fetal Development | 1 | 2002 | 92 | 0.010 |
Why?
| | Genetic Linkage | 1 | 2002 | 299 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2005 | 1291 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 757 | 0.010 |
Why?
| | Interleukins | 1 | 2003 | 241 | 0.010 |
Why?
| | Prognosis | 1 | 2010 | 3780 | 0.010 |
Why?
| | Recurrence | 1 | 2004 | 1004 | 0.010 |
Why?
| | Gene Rearrangement | 1 | 2002 | 147 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 2002 | 385 | 0.010 |
Why?
| | Pedigree | 1 | 2002 | 485 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2002 | 512 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 820 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 1273 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1455 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2005 | 715 | 0.010 |
Why?
| | Creatinine | 1 | 2002 | 480 | 0.010 |
Why?
| | Body Mass Index | 1 | 2009 | 2263 | 0.010 |
Why?
| | Safety | 1 | 2002 | 328 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1817 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2002 | 930 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2004 | 863 | 0.010 |
Why?
| | Kinetics | 1 | 2004 | 1624 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2008 | 3021 | 0.010 |
Why?
| | Apoptosis | 1 | 2009 | 2437 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2008 | 1276 | 0.010 |
Why?
| | Kidney Diseases | 1 | 2002 | 370 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2008 | 3947 | 0.010 |
Why?
| | Fetus | 1 | 2002 | 765 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2010 | 5371 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2008 | 5740 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2002 | 894 | 0.010 |
Why?
| | Hospitalization | 1 | 2005 | 2069 | 0.010 |
Why?
| | Risk Assessment | 1 | 2004 | 3232 | 0.010 |
Why?
| | Risk Factors | 1 | 2008 | 9737 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2002 | 2329 | 0.010 |
Why?
|
|
Zeitlin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|